185 related articles for article (PubMed ID: 32935597)
21. XALIA-LEA: An observational study of venous thromboembolism treatment with rivaroxaban and standard anticoagulation in the Asia-Pacific, Eastern Europe, the Middle East, Africa and Latin America.
Kreutz R; Mantovani LG; Haas S; Monje D; Schneider J; Bugge JP; Gebel M; Tamm M; Ageno W; Turpie AGG
Thromb Res; 2019 Apr; 176():125-132. PubMed ID: 30825694
[TBL] [Abstract][Full Text] [Related]
22. Evaluation of rivaroxaban use in patients with gynecologic malignancies at an academic medical center: A pilot study.
Signorelli JR; Gandhi AS
J Oncol Pharm Pract; 2019 Mar; 25(2):362-368. PubMed ID: 29157146
[TBL] [Abstract][Full Text] [Related]
23. Treatment Challenges in Venous Thromboembolism: An Appraisal of Rivaroxaban Studies.
Khorana AA; Weitz JI
Thromb Haemost; 2018 May; 118(S 01):S23-S33. PubMed ID: 29566417
[TBL] [Abstract][Full Text] [Related]
24. Effectiveness and safety of outpatient rivaroxaban versus warfarin for treatment of venous thromboembolism in patients with a known primary hypercoagulable state.
Coleman CI; Turpie AGG; Bunz TJ; Baker WL; Beyer-Westendorf J
Thromb Res; 2018 Mar; 163():132-137. PubMed ID: 29407625
[TBL] [Abstract][Full Text] [Related]
25. Cost-effectiveness of Apixaban Versus Other Oral Anticoagulants for the Initial Treatment of Venous Thromboembolism and Prevention of Recurrence.
Lanitis T; Leipold R; Hamilton M; Rublee D; Quon P; Browne C; Cohen AT
Clin Ther; 2016 Mar; 38(3):478-93.e1-16. PubMed ID: 26922297
[TBL] [Abstract][Full Text] [Related]
26. Rivaroxaban versus standard anticoagulation for symptomatic venous thromboembolism (REMOTEV observational study): Analysis of 6-month outcomes.
Gaertner S; Cordeanu EM; Nouri S; Faller AM; Frantz AS; Mirea C; Bilbault P; Ohlmann P; Le Ray I; Stephan D
Int J Cardiol; 2017 Jan; 226():103-109. PubMed ID: 27806307
[TBL] [Abstract][Full Text] [Related]
27. Comparing Length of Stay Between Patients Taking Rivaroxaban and Conventional Anticoagulants for Treatment of Venous Thromboembolism.
Desai A; Desai A; Calixte R; Aparnath M; Hindenburg A; Salzman S; Mathew JP
Lung; 2016 Aug; 194(4):605-11. PubMed ID: 27192990
[TBL] [Abstract][Full Text] [Related]
28. Patterns and Predictors of Use of Anticoagulants for the Treatment of Venous Thromboembolism Following Approval of Rivaroxaban.
Dault R; Vanasse A; Blais L; Perreault S; Farand P; Le Templier G; Beauchesne MF
Clin Appl Thromb Hemost; 2016 Nov; 22(8):765-771. PubMed ID: 26467323
[TBL] [Abstract][Full Text] [Related]
29. Rivaroxaban for the treatment of venous thromboembolism. The SWIss Venous ThromboEmbolism Registry (SWIVTER).
Kucher N; Aujesky D; Beer JH; Mazzolai L; Baldi T; Banyai M; Hayoz D; Kaeslin T; Korte W; Escher R; Husmann M; Frauchiger B; Baumgartner I; Spirk D
Thromb Haemost; 2016 Aug; 116(3):472-9. PubMed ID: 27346301
[TBL] [Abstract][Full Text] [Related]
30. New oral anticoagulants: comparative pharmacology with vitamin K antagonists.
Scaglione F
Clin Pharmacokinet; 2013 Feb; 52(2):69-82. PubMed ID: 23292752
[TBL] [Abstract][Full Text] [Related]
31. Profile of Patients Diagnosed With Acute Venous Thromboembolism in Routine Clinical Practice: The RE-COVERY DVT/PE™ Study.
Goldhaber SZ; Ageno W; Casella IB; Chee KH; Schellong S; Singer DE; Desch M; Reilly PA; Donado E; Tang W; Voccia I; Schulman S
Am J Med; 2020 Aug; 133(8):936-945. PubMed ID: 32325043
[TBL] [Abstract][Full Text] [Related]
32. A Retrospective Study on Efficacy and Safety of Rivaroxaban and Dalteparin for Long-Term Treatment of Venous Thromboembolism in Patients with Lung Cancer.
Lee JH; Hyun DG; Choi CM; Lee JC; Kim WS; Oh YM; Lee SD; Lee JS
Respiration; 2019; 98(3):203-211. PubMed ID: 31096241
[TBL] [Abstract][Full Text] [Related]
33. Efficacy and safety of Xa inhibitors for the treatment of cancer-associated venous thromboembolism.
Kimpton M; Carrier M
Expert Opin Drug Saf; 2019 Apr; 18(4):313-320. PubMed ID: 30925842
[TBL] [Abstract][Full Text] [Related]
34. New anticoagulants: focus on venous thromboembolism.
Gómez-Outes A; Lecumberri R; Pozo C; Rocha E
Curr Vasc Pharmacol; 2009 Jul; 7(3):309-29. PubMed ID: 19601856
[TBL] [Abstract][Full Text] [Related]
35. Rivaroxaban for the treatment of venous thromboembolism. A "real-life" perspective in 103 patients.
Jara-Palomares L; Sanchez-Oro-Gomez R; Elias-Hernandez T; Morillo-Guerrero R; Ferrer-Galvan M; Asensio-Cruz MI; Barrot-Cortes E; Otero-Candelera R
Thromb Res; 2014 Sep; 134(3):617-21. PubMed ID: 25034320
[TBL] [Abstract][Full Text] [Related]
36. An Update in Anticoagulant Therapy for Patients with Cancer-Associated Venous Thromboembolism.
Martins MA; Silva TF; Fernandes CJ
Curr Oncol Rep; 2023 May; 25(5):425-432. PubMed ID: 36928825
[TBL] [Abstract][Full Text] [Related]
37. A treatment strategy using subcutaneous fondaparinux followed by oral rivaroxaban is effective for treating acute venous thromboembolism.
Kabuki T; Nakanishi R; Hisatake S; Fujii T; Dobashi S; Wakakura S; Kiuchi S; Fujino T; Ikeda T
J Cardiol; 2017 Aug; 70(2):163-168. PubMed ID: 27979674
[TBL] [Abstract][Full Text] [Related]
38. Rivaroxaban in the cardiovascular world: a direct anticoagulant useful to prevent stroke and venous and arterial thromboembolism.
Seoane L; Cortés M; Aris Cancela ME; Furmento J; Baranchuk A; Conde D
Expert Rev Cardiovasc Ther; 2018 Jul; 16(7):501-514. PubMed ID: 29862875
[TBL] [Abstract][Full Text] [Related]
39. Evaluation of direct oral anticoagulants for the treatment of cancer-associated thrombosis: an update.
Franco-Moreno A; Cabezón-Gutiérrez L; Palka-Kotlowsa M; Villamayor-Delgado M; García-Navarro M
J Thromb Thrombolysis; 2019 Apr; 47(3):409-419. PubMed ID: 30467760
[TBL] [Abstract][Full Text] [Related]
40. Effectiveness and safety of rivaroxaban versus warfarin in obese patients with acute venous thromboembolism: analysis of electronic health record data.
Costa OS; Beyer-Westendorf J; Ashton V; Milentijevic D; Moore KT; Bunz TJ; Coleman CI
J Thromb Thrombolysis; 2021 Feb; 51(2):349-358. PubMed ID: 32588288
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
